Mather Group LLC. Sells 280 Shares of Eli Lilly and Company (NYSE:LLY)

Mather Group LLC. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,402 shares of the company’s stock after selling 280 shares during the period. Mather Group LLC.’s holdings in Eli Lilly and Company were worth $4,315,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares in the last quarter. Morgan Stanley increased its holdings in Eli Lilly and Company by 0.7% during the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after buying an additional 83,915 shares during the period. Northern Trust Corp raised its stake in Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after buying an additional 355,317 shares in the last quarter. International Assets Investment Management LLC raised its stake in Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after buying an additional 7,330,815 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Eli Lilly and Company by 2.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 4,435,311 shares of the company’s stock worth $2,382,339,000 after buying an additional 88,016 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.5 %

Eli Lilly and Company stock opened at $737.33 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52 week low of $392.26 and a 52 week high of $800.78. The stock has a 50-day moving average price of $760.89 and a 200 day moving average price of $668.00. The company has a market capitalization of $700.58 billion, a price-to-earnings ratio of 127.13, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.09 earnings per share. Sell-side analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LLY shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a report on Monday, April 15th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research note on Wednesday, February 21st. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Citigroup raised their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.